Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: Insights from the RESOLUTE trial

Circulation: Cardiovascular Interventions

Volumn 4, Issue 3, 2011, Pages 248-255

  Waseda, Katsuhisa ^a   Ako, Junya ^a   Yamasaki, Masao ^a   Koizumi, Tomomi ^a   Sakurai, Ryota ^a   Hongo, Yoichiro ^a   Koo, Bon Kwon ^a   Ormiston, John ^b   Worthley, Stephen G ^c   Whitbourn, Robert J ^d   Walters, Darren L ^e   Meredith, Ian T ^f   Fitzgerald, Peter J ^a   Honda, Yasuhiro ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e THE PRINCE CHARLES HOSPITAL   (Australia)

^f SOUTHERN HEALTH   (Australia)

Author keywords

Coronary disease; Drug eluting stent; Intravascular ultrasound

Indexed keywords

ENDEAVOR; POLYMER; RESOLUTE; UNCLASSIFIED DRUG; ZOMAXX; ZOTAROLIMUS;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FORMULATION; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; MALE; NEOINTIMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CELL PROLIFERATION; CORONARY ANGIOGRAPHY; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOINTIMA; POLYMERS; REGRESSION ANALYSIS; SIROLIMUS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84860388988     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.110.957548     Document Type: Article

References (27)

1. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D, Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E, Litvack F. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol. 2005;46:253-260. (Pubitemid 40966852)
2. Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M, Popma JJ, Cutlip DE, DePaoli A, Negoita M, Fitzgerald PJ. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. J Am Coll Cardiol Intv. 2009;2:977-985.
3. Waseda K, Ako J, Yamasaki M, Koizumi T, Ormiston J, Worthley SG, Whitbourn RJ, Walters DL, Honda Y, Meredith IT, Fitzgerald PJ. Short-and mid-term intravascular ultrasound analysis of the new zotarolimus-eluting stent with durable polymer. Circ J. 2010;74:2097-2102.
4. Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, Cutlip D, Popma JJ, Zimetbaum P, Fajadet J, Kuntz RE, Wijns W, Fitzgerald PJ. Detailed intravascular ultrasound analysis of zotarolimus-eluting phosphorylcholine- coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol. 2007;100:818-823.
5. Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, Hassan AH, Kandzari DE, Honda Y, Fitzgerald PJ. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intra-vascular ultrasound results from ENDEAVOR III. Am Heart J. 2008;155: 108-113. (Pubitemid 350234763)
6. Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, Yock PG, Honda Y, Kandzari DE, Leon MB, Fitzgerald PJ. Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus-and paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol Intv. 2009;2:779-784.
7. Chevalier B, Di Mario C, Neumann FJ, Ribichini F, Urban P, Popma JJ, Fitzgerald PJ, Cutlip DE, Williams DO, Ormiston J, Grube E, Whitbourn R, Schwartz LB. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus-versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: the ZoMaxx I trial. J Am Coll Cardiol Intv. 2008;1:524-532.
8. Waseda K, Hasegawa T, Ako J, Honda Y, Grube E, Whitbourn R, Ormiston J, O'Shaughnessy CD, Henry TD, Overlie P, Schwartz LB, Sudhir K, Chevalier B, Gray WA, Yeung AC, Fitzgerald PJ. Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials. Circ J. 2010;74:2334-2339.
9. Kataoka T, Grube E, Honda Y, Morino Y, Hur SH, Bonneau HN, Colombo A, Di Mario C, Guagliumi G, Hauptmann KE, Pitney MR, Lansky AJ, Stertzer SH, Yock PG, Fitzgerald PJ. 7-Hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation. 2002;106:1788-1793.
10. Ako J, Morino Y, Honda Y, Hassan A, Sonoda S, Yock PG, Leon MB, Moses JW, Bonneau HN, Fitzgerald PJ. Late incomplete stent apposition after sirolimus-eluting stent implantation: a serial intravascular ultrasound analysis. J Am Coll Cardiol. 2005;46:1002-1005. (Pubitemid 41316506)
11. Pinto Slottow TL, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel meeting on the Endeavor zotarolimus-eluting coronary stent. Circulation. 2008;117: 1603-1608.
12. DuVall M, Qin JL, Clifford A, Barry CM, Nowak SA, Sabaj KM, Zielinski DA, Smits G, Zhang J, Cromack K, Dube H, Schwartz LB, Krasula RW. ABT-578 elution profile and arterial penetration using the ZoMaxx drug-eluting stent. Am J Cardiol. 2004;94(Suppl):223E.
13. Meredith IT, Worthley S, Whitbourn R, Walters D, Popma J, Cutlip D, Fitzgerald PJ. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention. 2007;3:50-53.
14. Koo BK, Waseda K, Ako J, Hasegawa T, Shimohama T, Nakatani D, Otake H, Yamasaki M, Sakurai R, Tsujino I, Honda Y, Fitzgerald PJ. Incidence of diffuse and focal chronic stent recoil after implantation of current generation bare-metal and drug-eluting stents. Int J Cardiol. 2010;144:132-134.
15. Aoki J, Nakazawa G, Tanabe K, Hoye A, Yamamoto H, Nakayama T, Onuma Y, Higashikuni Y, Otsuki S, Yagishita A, Yachi S, Nakajima H, Hara K. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv. 2007; 69:380-386. (Pubitemid 46339279)
16. Kim JS, Lee SY, Lee JM, Yoon YW, Ahn CM, Kim MH, Min PK, Ko YG, Hong BK, Choi D, Kwon HM, Jang Y, Shim WH. Significant association of coronary stent fracture with in-stent restenosis in sirolimus-eluting stents. Coron Artery Dis. 2009;20:59-63.
17. Takebayashi H, Mintz GS, Carlier SG, Kobayashi Y, Fujii K, Yasuda T, Costa RA, Moussa I, Dangas GD, Mehran R, Lansky AJ, Kreps E, Collins MB, Colombo A, Stone GW, Leon MB, Moses JW. Nonuniform strut distribution correlates with more neointimal hyperplasia after sirolimus-eluting stent implantation. Circulation. 2004;110:3430-3434. (Pubitemid 39602221)
18. Hasegawa T, Ako J, Ikeno F, Waseda K, Suzuki Y, Honda Y, Fitzgerald PJ. Comparison of nonuniform strut distribution between two drug-eluting stent platforms. J Invasive Cardiol. 2007;19:244-246. (Pubitemid 46828010)
19. Hong MK, Mintz GS, Lee CW, Park DW, Park KM, Lee BK, Kim YH, Song JM, Han KH, Kang DH, Cheong SS, Song JK, Kim JJ, Park SW, Park SJ. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation. 2006;113:414-419. (Pubitemid 43803203)
20. Degertekin M, Serruys PW, Tanabe K, Lee CH, Sousa JE, Colombo A, Morice MC, Ligthart JM, de Feyter PJ. Long-term follow-up of incomplete stent apposition in patients who received sirolimus-eluting stent for de novo coronary lesions: an intravascular ultrasound analysis. Circulation. 2003;108:2747-2750. (Pubitemid 37498975)
21. Tanabe K, Serruys PW, Degertekin M, Grube E, Guagliumi G, Urbaszek W, Bonnier J, Lablanche JM, Siminiak T, Nordrehaug J, Figulla H, Drzewiecki J, Banning A, Hauptmann K, Dudek D, Bruining N, Hamers R, Hoye A, Ligthart JM, Disco C, Koglin J, Russell ME, Colombo A. Incomplete stent apposition after implantation of paclitaxel-eluting stents or bare metal stents: insights from the randomized TAXUS II trial. Circulation. 2005;111:900-905. (Pubitemid 40279892)
22. Weissman NJ, Ellis SG, Grube E, Dawkins KD, Greenberg JD, Mann T, Cannon LA, Cambier PA, Fernandez S, Mintz GS, Mandinov L, Koglin J, Stone GW. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. Eur Heart J. 2007;28:1574-1582. (Pubitemid 47227125)
23. Feres F, Costa JR Jr, Abizaid A. Very late thrombosis after drug-eluting stents. Catheter Cardiovasc Interv. 2006;68:83-88. (Pubitemid 44024467)
24. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426-2434. (Pubitemid 46717965)
25. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193-202. (Pubitemid 43929240)
26. Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbaek H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, DiMario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita M, van Leeuwen F, Windecker S. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med. 2010;363:136-146.
27. Hezi-Yamit A, Sullivan C, Wong J, David L, Chen M, Cheng P, Shumaker D, Wilcox JN, Udipi K. Impact of polymer hydrophilicity on biocompatibility: implication for DES polymer design. J Biomed Mater Res A. 2009;90:133-141.